Concurrent Investment Advisors’s AbbVie ABBV Stock Holding History

Concurrent Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.96M	Hold	23,700	–	–	0.05%	390
2026 Q1	$5.15M	Sell	23,700 -25,700	-52%	-$5.7M	0.06%	350
2025 Q4	$11.3M	Buy	49,400 +25,700	+108%	+$5.85M	0.13%	165
2025 Q3	$5.49M	Buy	23,700 +13,400	+130%	+$2.73M	0.09%	222
2025 Q2	$1.91M	Buy	+10,300	New	+$1.91M	0.04%	441

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Concurrent Investment Advisors's ABBV Position: Q2 2026 in Review

Concurrent Investment Advisors increased its AbbVie (ABBV) stake by 2.5% in Q2 2026, buying an estimated $845K and bringing the position to 160,023 shares worth $40.3M. The position accounts for 0.34% of the portfolio, ranked #56.

Concurrent Investment Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Concurrent Investment Advisors held 160,023 shares of AbbVie worth $40.3M as of Q2 2026.
Concurrent Investment Advisors bought 3,926 AbbVie shares in Q2 2026, an estimated $845K.
AbbVie made up 0.34% of Concurrent Investment Advisors's portfolio in Q2 2026, its #56 holding.
Concurrent Investment Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.